Table 3.

Partial oncogene proteins related to breast cancer

Protein	Protein description	References
HER‐2	HER‐2 as therapeutic and prognostic biomarker plays a significant role in Human BC. It is found that adenomas and carcinomas have higher levels of HER‐2 protein than normal mammary glands	163
CA125	CA125 as a predictive marker of ovarian/breast carcinoma, it depends on disease nature/stages. CA125 plays an interactive role in the disease processes, and it is closely related to BC	164
CA19‐9	Levels of CA19‐9 are correlated with treatment response and survival of BC	165
MUC1	MUC1‐MBP is a member of the mucins family, and it is present in normal glandular epithelial cells and tumour cells. MUC1‐MBP consists of a polypeptide core and a side chain sugar chain. MUC1‐MBP widely distributed on the surface of BC cells	166
ER	ER in the pathophysiology of BC plays an important role, and it as an index can be used to guide pharmacy for BC patients	167
CypB	BC tissues have higher levels of CypB proteins than para cancerous tissues. Functional study confirms that downregulation levels of CypB may inhibit tumour cell growth, proliferation and migration	168
CA153	When the breast becomes cancerous, the activities of protease and salivary enzyme are increased, causing destruction of the cytoskeleton of the gland, causing CA153 saccharide antigen generally separated from the cancer cell membrane and releasing into the blood. It is an important index for screening BC	169
CEA	CEA is an acidic glycoprotein with a specific determinant of human embryonic antigen. It is a broad‐spectrum tumour marker that can be expressed in a variety of tumours. It is also elevated in the serum of patients with BC, lung cancer and other malignant tumours	170
PR	Analysis of PR proteins remains controversial in BC. The level of PR + is related to age of BC patients. The deletion of PR proteins might cause BC	98